Physician profile
Brinders Jones
NPI 1205854676
$1,009.81
in general payments reported to CMS, 2019-2025
15 companies · $109 in 2025
The $109 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $144 · 2021: $102 · 2022: $308 · 2023: $34.63 · 2024: $30.78 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $174.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $174.92 | 2020-2022 | |
| Abbott Laboratories | $159.78 | 2022 | |
| Pfizer INC. | $136.93 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $110.60 | 2019-2021 | |
| Tris Pharma INC | $102.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $98.35 | 2019 | |
| Glaxosmithkline, LLC. | $45.92 | 2019-2023 | Pediarix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $30.78 | 2024 | Flumist Quadrivalent |
| Merck Sharp & Dohme LLC | $29.06 | 2019-2025 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Seqirus USA INC | $28.14 | 2025 | Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $25.38 | 2020 | |
| Mylan Pharmaceuticals INC. | $18.19 | 2019 | |
| Cranial Technologies, INC | $16.97 | 2025 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $16.79 | 2025 | Zoryve |
| Dexcom, INC. | $15.72 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brinders Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.